Malorye Allison Branca

4 days ago | insideprecisionmedicine.com | Malorye Allison Branca

The largest study ever conducted on individuals with cardiovascular disease finds that in those with atherosclerotic cardiovascular disease (ASCVD), risk of recurrent cardiovascular events continues to rise across all ascending levels of Lp(a), with no indication of risk plateauing. This finding is contrary to earlier research. These findings were presented on May 7th at the European Atherosclerosis Society (EAS). They were simultaneously published in the European Heart Journal.

1 week ago | insideprecisionmedicine.com | Malorye Allison Branca

A team led by researchers at Mayo Clinic have used proprietary algorithms and genetic data to develop a risk score that predicts which patients are most likely to experience GI side effects from GLP-1 agonists such as Wegovy and Zepbound. Such effects impact up to 70% of patients. Nausea is the most common reason people discontinue GLP-1s. In this study, patients with certain genetic markers were more than twice as likely to experience nausea from GLP-1s compared to others (68% vs. 30%).

1 week ago | insideprecisionmedicine.com | Malorye Allison Branca

Over 7.4 million UK adults’ anonymized electronic health records were used to create two new algorithms to predict a seemingly cancer-free patient’s chances of actually having the disease. The predictive algorithms use information about a person’s health conditions and results from simple blood tests. They were developed by researchers from Queen Mary University of London and the University of Oxford.

1 week ago | insideprecisionmedicine.com | Malorye Allison Branca

Avenda Health has announced new study results showing its cancer mapping tool, Unfold AI, predicts prostate cancer spread more accurately than MRI. The study was led by Stanford and UCLA researchers. Unfold AI is the first and only FDA-approved AI-based prostate cancer decision support program. The pilot study, titled “Prediction of Seminal Vesicle Invasion Using Artificial Intelligence Prostate Cancer Risk Mapping,” was presented at the American Urological Association’s 2025 Annual Meeting.

1 week ago | insideprecisionmedicine.com | Malorye Allison Branca

A preterm infant with a genetic disease had the frequency of her seizures reduced by more than half after Ludwig-Maximilians-Universität München-led researchers treated her with elsunersen, an antisense oligonucleotide that specifically targets her condition. The drug is still in development, so this was done under expanded access. The study appears in Nature Medicine.